Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23, 09:00-12:00
Protheragen Session: Global Biomedical Cross-Border Transactions
Stay tuned
09:00-09:05 Opening & Welcome Remarks
Protheragen
09:05-09:20 Biopharma Innovation and Globalization - Challenges and Strategies
Pauline Lau:Suntec Medical, Inc. CEO
09:20-09:35 TBD
Sean He:Novo Holdings A/S Partner and Head of China
09:35-09:50 Bridging Early-Stage Science Across Borders: How Venture Capital Connects Global Biotech Innovation
Alexis Ji:Primer Ventures Founding Partner
09:50-10:05 Partnering trends and opportunities in Europe
Jose-Maria Fernandez:Asabys Partners、AltamarCAM Partners
10:05-10:20 TBD
Natasha Qin:Sun Pharmaceutical Industries Limited Senior Director BD
10:20-10:35 How Investors and Strategic Partners Assess Biopharma Assets: Lessons for Cross-Border Positioning and Readiness
Meghal Mistry:Zydus Lifesciences Limited Deputy General Manager of Business and Strategy
10:35-10:50 Accessing emerging markets in Asia and Africa: market needs, partnership models, and experiences from reach52
Edward Booty:Reach52 Pte. Ltd CEO
10:50-11:05 TBD
Josep-Maria Casanovas:Almirall Vice President, External Innovation & Licensing
11:05-12:00 Panel Discussion:From Interest to Execution: How Cross-Border BiopharmaCollaboration Works Today
Babar Khan:NEOM Investment Fund
Jasmine Wang:General Manager of Astellas (Beijing) Pharmaceutical R&D Co.,Ltd., Head of China Development
Ester Caffarel-Salvador:Chiesi Global Rare Diseases Director Strategic Innovation Global Rare Disease
Jason Peng:Santen Head of China Business Development, GBD
Calvin Chen:Novo Nordisk Associate Director Global Search & Evaluation
Josep-Maria Casanovas:Almirall Vice President, External Innovation & Licensing